Recently, inhibiting immune checkpoints, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed death 1 (PD1), and programmed death-ligand 1 (PD-L1), has shown clear benefits in the survival of cancer patients (Larkin et al., 2015; Bellmunt et al., 2017; Garassino et al., 2020). The gene discussed is CTLA4; the disease is cancer.